Alterity Therapeutics Ltd (ATHE) - Total Liabilities
Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) has total liabilities worth $3.29 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Alterity Therapeutics Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Alterity Therapeutics Ltd - Total Liabilities Trend (1998–2026)
This chart illustrates how Alterity Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Alterity Therapeutics Ltd total assets.
Alterity Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Alterity Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Saigon Thuong Tin Real Estate JSC
VN:SCR
|
Vietnam | ₫7.55 Trillion |
|
Full House Resorts Inc
NASDAQ:FLL
|
USA | $643.43 Million |
|
St. James's Place plc
LSE:STJ
|
UK | GBX244.92 Billion |
|
Skarbiec Holding S.A.
WAR:SKH
|
Poland | zł740.92 Million |
|
Courtside Group, Inc. Common Stock
NASDAQ:PODC
|
USA | $8.31 Million |
|
Flag Ship Acquisition Corp. Unit
NASDAQ:FSHPU
|
USA | $2.93 Million |
|
GOLDGROUP MINING INC.
F:55G0
|
Germany | €73.31 Million |
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
USA | $3.26 Million |
Liability Composition Analysis (1998–2026)
This chart breaks down Alterity Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Alterity Therapeutics Ltd (ATHE) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alterity Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alterity Therapeutics Ltd (1998–2026)
The table below shows the annual total liabilities of Alterity Therapeutics Ltd from 1998 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $3.29 Million | -9.07% |
| 2025-06-30 | $3.62 Million | -33.22% |
| 2024-06-30 | $5.43 Million | +20.44% |
| 2023-06-30 | $4.50 Million | -23.57% |
| 2022-06-30 | $5.89 Million | +89.20% |
| 2021-06-30 | $3.12 Million | +13.00% |
| 2020-06-30 | $2.76 Million | -17.83% |
| 2019-06-30 | $3.36 Million | +26.86% |
| 2018-06-30 | $2.64 Million | +66.25% |
| 2017-06-30 | $1.59 Million | -32.53% |
| 2016-06-30 | $2.36 Million | -13.35% |
| 2015-06-30 | $2.72 Million | -31.19% |
| 2014-06-30 | $3.95 Million | +27.60% |
| 2013-06-30 | $3.10 Million | +80.35% |
| 2012-06-30 | $1.72 Million | -17.37% |
| 2011-06-30 | $2.08 Million | +32.29% |
| 2010-06-30 | $1.57 Million | +85.51% |
| 2009-06-30 | $847.43K | -53.84% |
| 2008-06-30 | $1.84 Million | -12.97% |
| 2007-06-30 | $2.11 Million | +24.62% |
| 2006-06-30 | $1.69 Million | -36.93% |
| 2005-06-30 | $2.68 Million | -0.46% |
| 2004-06-30 | $2.70 Million | +377.62% |
| 2003-06-30 | $564.54K | -38.15% |
| 2002-06-30 | $912.82K | +2.04% |
| 2001-06-30 | $894.58K | +507.99% |
| 2000-06-30 | $147.14K | -92.33% |
| 1999-06-30 | $1.92 Million | +859.02% |
| 1998-06-30 | $199.96K | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more